Answers are grounded in this paper and cite their sources.
Establish biorepository of blood-based biomarkers for neurodegenerative diseases (ND); assess feasibility of biomarker collection/processing in subjects at risk for dementia; incorporate concurrent phenotypic clinical data; and explore utility of blood-based biomarkers as outcome measures for n-of-1 trials.
No takes yet. Share an insight, caveat, or question.
Sisser et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: